Chugai Pharmaceutical (4519) secures MHLW approval for expanded Alecensa indication
Chugai Pharmaceutical Co., Ltd. has secured manufacturing and marketing approval from Japan's Ministry of Health, Labour and Welfare for an expanded indication of its anti-cancer drug, Alecensa (Alectinib). The approval covers advanced or recurrent solid tumours with ALK fusion genes, including paediatric patients, marking the world's first tumour-agnostic approval for an ALK inhibitor. The company's shares (4519) are trading at ¥7,860, up 0.3% from yesterday's close.
This regulatory decision advances personalised medicine by offering a treatment option for patients with specific genetic mutations, irrespective of cancer type. Complementing this, Chugai Pharmaceutical also obtained MHLW approval on 9 March 2026, for FoundationOne®CDx cancer genomic profile as a companion diagnostic for Alecensa in ALK fusion gene-positive solid tumours. This dual approval strengthens the company's oncology portfolio.
The modest gain today follows a 0.7% rise on 21 May 2026, when news of the expanded Alecensa approval was reported, as detailed in prior coverage: Chugai Pharmaceutical (4519) wins expanded Japanese approval for cancer drug Alecensa. Chugai shares are currently trading above their previous close of ¥7,836.
Why Chugai's tumour-agnostic drug approval matters for personalised medicine
Chugai Pharmaceutical is a leading Japanese drugmaker focused on discovering, developing, and selling innovative medicines. They generate revenue by creating treatments for unmet medical needs, particularly in areas like cancer, bone and joint conditions, and kidney diseases, leveraging advanced biotechnology to improve patients' quality of life.
The specific driver behind Chugai's share price movement today is the Ministry of Health, Labour and Welfare's approval for their anti-cancer drug, Alecensa. This groundbreaking decision means Alecensa can now be used to treat solid tumours that possess a particular genetic mutation, irrespective of where the cancer originated in the body. Announced on 18 May 2026, this marks the world's first tumour-agnostic approval for an ALK inhibitor, signifying a major advance in personalised medicine.
This pivotal regulatory nod has seen Chugai's shares rise by 0.3%, trading at ¥7,860, up from yesterday's close of ¥7,836. This modest gain reflects the market's positive outlook on the company's strengthened product portfolio.
Think of it like a specialist engine part that was previously certified for use in only one specific car model. Now, it has been officially approved for installation across a wide range of different car types, provided they share a particular engine characteristic. This broader applicability significantly increases the part's potential market and inherent value.
Chugai Pharmaceutical Co., Ltd.
Chugai Pharmaceutical Co., Ltd. (4519) is a Japanese healthcare firm specialising in the research, development, manufacturing, and global distribution of pharmaceutical products. Its diverse portfolio includes treatments for oncology, such as Avastin and Tecentriq; osteoporosis, with products like Actemra; and renal conditions, including Mircera. The company also addresses neurological and other diseases, notably with Hemlibra and Enspryng. Chugai maintains strategic alliances with the Roche Group and engages in collaborative research with academic institutions. Established in 1925, the company operates as a subsidiary of Roche Holding Ltd. and is headquartered in Tokyo, Japan.